New drug cocktail aims to wipe out tough breast cancers before surgery

This study tests whether adding a targeted drug called inavolisib to standard treatment can better eliminate breast cancer before surgery in people with a specific genetic mutation (PIK3CA) and HER2-positive early breast cancer. About 164 participants will receive either the standard therapy or the standard therapy plus inavolisib for about 18 weeks before surgery. The main goal is to see if the new combination leads to a higher rate of no cancer remaining in the breast and lymph nodes at the time of surgery.